VTRS - Despite Efforts Vulnerable Patients Still Face Barriers to Essential Medicines Says New Report (UPDATED) | Benzinga
Editor's note: This article has been updated with more details from the Access to Medicine Foundation's study.
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to Medicine Foundation.
Remarkably, of the 50 products examined from five major generic drug firms, only one had a pricing strategy aligned with patients' affordability in low-to-middle-income nations.
The five generic drug makers in the spotlight include Cipla Ltd, Hikma Pharmaceuticals Plc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd (NYSE: